Previously announced preliminary interim results from intralymphatic study with Diamyd® published in the New England Journal of Medicine

Diamyd Medical announced that an article by Professor Johnny Ludvigsson, Principal Investigator and sponsor of DIAGNODE-1, an intra-lymphatic pilot study with Diamyd®, was published today in the scientific journal New England Journal of Medicine.

The article summarizes the preliminary interim results based on study data from six patients who have been followed for at least six months, of which four have been followed for at least 15 months, which Diamyd Medical previously announced in a press release on October 24, 2016.

DIAGNODE-1 is an open label pilot study, comprising a total of fifteen patients between the ages of 12 and 30 with type 1 diabetes, where a low dose of the diabetes vaccine Diamyd
® is administered directly into the lymph node in combination with treatment with vitamin D.

The article is available on

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. At this time six clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail:

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: Reg. no.: 556242-3797. Website:

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. This is an English translation of information that was submitted for publication, through the agency of the contact person set out above, at 10:25 CET on February 16, 2017.


About Us

Diamyd Medical is a Swedish diabetes company dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell- and medical technology.


Documents & Links